TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spinal Cord Stimulation for Refractory Pain in Erythromelalgia
Brief Summary: Erythromelalgia is a rare disorder characterized by red, warm, and painful extremities, which is often precipitated by warm conditions. The pathophysiology is incompletely understood. The management of pain in erythromelalgia is challenging as no single therapy has been found to be effective. Response to pharmacotherapy varies, meaning that the physician has to take a stepwise trial and error approach with each patient. Consequently, this disorder is often associated with poorer health-related quality of life. There is currently no consensus or guideline on management of pain in erythromelalgia. Spinal cord stimulation is a widely applied therapy to treat severe chronic pain of various origin. Case reports and anecdotal evidence suggest that this therapy might alleviate refractory pain in patients with erythromelalgia.

The aim of this trial is to evaluate the efficacy of spinal cord stimulation for refractory pain in erythromelalgia.


Options:
A: Arm Label: Burst spinal cord stimulation (SCS); Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Arm Label: sham spinal cord stimulation (SCS); Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS) | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS)
B: Arm Label: Spinal Cord Stimulation (SCS); Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal Cord Stimulation | Arm Label: Conventional Medical Management (CMM); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Medical Management | Intervention Type: DEVICE; Name: Spinal Cord Stimulation; Assigned to Arm(s): Spinal Cord Stimulation (SCS) | Intervention Type: OTHER; Name: Conventional Medical Management; Assigned to Arm(s): Conventional Medical Management (CMM)
C: Arm Label: Burst SCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10) | Intervention Type: DEVICE; Name: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10); Assigned to Arm(s): Burst SCS, Sham
D: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spinal Cord Stimulation for Refractory Pain in Erythromelalgia
Brief Summary: Erythromelalgia is a rare disorder characterized by red, warm, and painful extremities, which is often precipitated by warm conditions. The pathophysiology is incompletely understood. The management of pain in erythromelalgia is challenging as no single therapy has been found to be effective. Response to pharmacotherapy varies, meaning that the physician has to take a stepwise trial and error approach with each patient. Consequently, this disorder is often associated with poorer health-related quality of life. There is currently no consensus or guideline on management of pain in erythromelalgia. Spinal cord stimulation is a widely applied therapy to treat severe chronic pain of various origin. Case reports and anecdotal evidence suggest that this therapy might alleviate refractory pain in patients with erythromelalgia.

The aim of this trial is to evaluate the efficacy of spinal cord stimulation for refractory pain in erythromelalgia.


Options:
A: Arm Label: Burst SCS; Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation, Device: SCS implant | Arm Label: Sham SCS; Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation, Device: SCS implant | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst SCS, Sham SCS | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst SCS, Sham SCS | Intervention Type: DEVICE; Name: SCS implant; Assigned to Arm(s): Burst SCS, Sham SCS
B: Arm Label: Burst spinal cord stimulation (SCS); Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Arm Label: sham spinal cord stimulation (SCS); Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS) | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS)
C: Arm Label: Sequence 1; Type: OTHER; Interventions: Device: High frequency spinal cord stimulation | Arm Label: Sequence 2; Type: OTHER; Interventions: Device: High frequency spinal cord stimulation | Intervention Type: DEVICE; Name: High frequency spinal cord stimulation; Assigned to Arm(s): Sequence 1, Sequence 2
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: PINS Spinal Cord Stimulator | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: PINS Spinal Cord Stimulator | Intervention Type: DEVICE; Name: PINS Spinal Cord Stimulator; Assigned to Arm(s): Control, Experimental

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spinal Cord Stimulation for Refractory Pain in Erythromelalgia
Brief Summary: Erythromelalgia is a rare disorder characterized by red, warm, and painful extremities, which is often precipitated by warm conditions. The pathophysiology is incompletely understood. The management of pain in erythromelalgia is challenging as no single therapy has been found to be effective. Response to pharmacotherapy varies, meaning that the physician has to take a stepwise trial and error approach with each patient. Consequently, this disorder is often associated with poorer health-related quality of life. There is currently no consensus or guideline on management of pain in erythromelalgia. Spinal cord stimulation is a widely applied therapy to treat severe chronic pain of various origin. Case reports and anecdotal evidence suggest that this therapy might alleviate refractory pain in patients with erythromelalgia.

The aim of this trial is to evaluate the efficacy of spinal cord stimulation for refractory pain in erythromelalgia.


Options:
A: Arm Label: Burst spinal cord stimulation (SCS); Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Arm Label: sham spinal cord stimulation (SCS); Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS) | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS)
B: Arm Label: Group A - active treatment; Type: EXPERIMENTAL; Interventions: Device: Spinal cord stimulation by implanted device. | Arm Label: Group B - conservative management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spinal cord stimulation by implanted device.; Assigned to Arm(s): Group A - active treatment
C: Arm Label: HF10 therapy plus CMM; Type: ACTIVE_COMPARATOR; Interventions: Device: Senza HF10 Therapy | Arm Label: CMM Alone; Type: OTHER; Interventions: Other: CMM | Intervention Type: DEVICE; Name: Senza HF10 Therapy; Assigned to Arm(s): HF10 therapy plus CMM | Intervention Type: OTHER; Name: CMM; Assigned to Arm(s): CMM Alone
D: Arm Label: Spinal Cord Stimulation; Type: EXPERIMENTAL; Interventions: Device: WaveWriter | Arm Label: Conventional Medical Management; Type: OTHER; Interventions: Other: Conventional Medical Managament | Intervention Type: DEVICE; Name: WaveWriter; Assigned to Arm(s): Spinal Cord Stimulation | Intervention Type: OTHER; Name: Conventional Medical Managament; Assigned to Arm(s): Conventional Medical Management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 3 Months and Older) With Mild-to-Moderate Atopic Dermatitis, Who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment
Brief Summary: This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.


Options:
A: Arm Label: Dicillin & Elocon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dicloxacillin Oral Capsule, Drug: Elocon 0.1 % Topical Cream | Arm Label: Placebo & Elocon; Type: PLACEBO_COMPARATOR; Interventions: Drug: Elocon 0.1 % Topical Cream | Intervention Type: DRUG; Name: Dicloxacillin Oral Capsule; Assigned to Arm(s): Dicillin & Elocon | Intervention Type: DRUG; Name: Elocon 0.1 % Topical Cream; Assigned to Arm(s): Dicillin & Elocon, Placebo & Elocon
B: Arm Label: Crisaborole 2%; Type: EXPERIMENTAL; Interventions: Drug: Crisaborole 2% | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: Crisaborole 2%; Assigned to Arm(s): Crisaborole 2% | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
C: Arm Label: Crisaborole ointment; Type: EXPERIMENTAL; Interventions: Drug: Crisaborole ointment 2% BID | Arm Label: Placebo ointment (vehicle); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ointment (vehicle) | Intervention Type: DRUG; Name: Crisaborole ointment 2% BID; Assigned to Arm(s): Crisaborole ointment | Intervention Type: DRUG; Name: Placebo ointment (vehicle); Assigned to Arm(s): Placebo ointment (vehicle)
D: Arm Label: AN2728 Topical Ointment, 2%; Type: EXPERIMENTAL; Interventions: Drug: AN2728 Topical Ointment, 2% | Arm Label: Matching vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching vehicle control | Intervention Type: DRUG; Name: AN2728 Topical Ointment, 2%; Assigned to Arm(s): AN2728 Topical Ointment, 2% | Intervention Type: DRUG; Name: Matching vehicle control; Assigned to Arm(s): Matching vehicle control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduction of Visual and Auditory Stimuli to Reduce Pain During Venipuncture in Premature Infants. A Randomized Controlled Trial.
Brief Summary: The aim of the study is: To evaluate the efficacy of the reduction of visual and auditory stimuli on pain during venipuncture in premature newborns of 32-36 weeks of gestation.


Options:
A: Arm Label: Language Treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Language Treatment | Arm Label: Control Treatment Arm; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Treatment | Intervention Type: BEHAVIORAL; Name: Language Treatment; Assigned to Arm(s): Language Treatment Arm | Intervention Type: BEHAVIORAL; Name: Control Treatment; Assigned to Arm(s): Control Treatment Arm
B: Arm Label: Early Vocal Contact; Type: EXPERIMENTAL; Interventions: Behavioral: Early Vocal Contact | Arm Label: Behavioral observation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Observation | Intervention Type: BEHAVIORAL; Name: Early Vocal Contact; Assigned to Arm(s): Early Vocal Contact | Intervention Type: BEHAVIORAL; Name: Behavioral Observation; Assigned to Arm(s): Behavioral observation
C: Arm Label: Stimuli Reduction; Type: EXPERIMENTAL; Interventions: Procedure: Stimuli reduction | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Intervention Type: PROCEDURE; Name: Stimuli reduction; Assigned to Arm(s): Stimuli Reduction | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual Care
D: Arm Label: Multisensory Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Therapist skin-to-skin Care, Device: Contingent parent's voice exposure, Behavioral: Parental skin-to-skin care, Device: Recorded parent's voice | Arm Label: Standard of Care; Type: OTHER; Interventions: Behavioral: Parental skin-to-skin care, Device: Recorded parent's voice | Intervention Type: BEHAVIORAL; Name: Therapist skin-to-skin Care; Assigned to Arm(s): Multisensory Intervention | Intervention Type: DEVICE; Name: Contingent parent's voice exposure; Assigned to Arm(s): Multisensory Intervention | Intervention Type: BEHAVIORAL; Name: Parental skin-to-skin care; Assigned to Arm(s): Multisensory Intervention, Standard of Care | Intervention Type: DEVICE; Name: Recorded parent's voice; Assigned to Arm(s): Multisensory Intervention, Standard of Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis
Brief Summary: This study evaluated the long-term safety and tolerability of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) triple combination (TC) treatment in participants with cystic fibrosis (CF).


Options:
A: Arm Label: GLPG2222 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 150 mg q.d. | Arm Label: GLPG2222 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 300 mg q.d. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 150 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 1 | Intervention Type: DRUG; Name: GLPG2222 300 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA
C: Arm Label: Phenylbutyrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium 4-Phenylbutyrate, Drug: Genistein (Unconjugated Isoflavones 100) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Genistein (Unconjugated Isoflavones 100), Drug: Placebo | Intervention Type: DRUG; Name: Sodium 4-Phenylbutyrate; Assigned to Arm(s): Phenylbutyrate | Intervention Type: DRUG; Name: Genistein (Unconjugated Isoflavones 100); Assigned to Arm(s): Phenylbutyrate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Demarcation Line Depth in Transepithelial Versus Epithelium-off Accelerated Cross-linking (AXL) in Keratocouns
Brief Summary: To assess depth of demarcation line in transepithelial versus epithelium-off accelerated cross-linking in keratoconus patients


Options:
A: Arm Label: Riboflavin 0.1% eyedrops every 5 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin, Device: UVX light | Arm Label: Riboflavin 0.1% eyedrops every 2 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin, Device: UVX light | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Riboflavin 0.1% eyedrops every 2 minutes, Riboflavin 0.1% eyedrops every 5 minutes | Intervention Type: DEVICE; Name: UVX light; Assigned to Arm(s): Riboflavin 0.1% eyedrops every 2 minutes, Riboflavin 0.1% eyedrops every 5 minutes
B: Arm Label: Transepithelial accelerated cross-linking; Type: ACTIVE_COMPARATOR; Interventions: Procedure: corneal cross-linking | Arm Label: Epithelium-off accelerated cross-linking; Type: ACTIVE_COMPARATOR; Interventions: Procedure: corneal cross-linking | Intervention Type: PROCEDURE; Name: corneal cross-linking; Assigned to Arm(s): Epithelium-off accelerated cross-linking, Transepithelial accelerated cross-linking
C: Arm Label: CXL without epithelial removal; Type: EXPERIMENTAL; Interventions: Procedure: CXL without epithelial removal | Arm Label: CXL with epithelial removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CXL with epithelial removal | Intervention Type: PROCEDURE; Name: CXL without epithelial removal; Assigned to Arm(s): CXL without epithelial removal | Intervention Type: PROCEDURE; Name: CXL with epithelial removal; Assigned to Arm(s): CXL with epithelial removal
D: Arm Label: total removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (total removal) | Arm Label: partial removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (partial removal) | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (total removal); Assigned to Arm(s): total removal | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (partial removal); Assigned to Arm(s): partial removal

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To test the hypothesis that correction with bifocal spectacle lenses rather than single-vision lenses will slow the progression of myopia in children with near-point esophoria. The primary outcome variable is cycloplegic refraction as measured with an automated refractor. Axial length is measured with ultrasound in order to test the corollary hypothesis that use of bifocals will slow ocular growth in these myopic children. We will also examine the amount of close work performed by subjects and the degree of parental myopia as factors that may influence myopia progression.


Options:
A: Boys must have been between 6 and 12 years of age; girls between 6 and 11 years of age. All children must have had at least 0.5 diopters of myopia in both eyes, near-point esophoria, at least 20/25 acuity in each eye, and 40 seconds of stereopsis and must have been free of ocular disease or systemic disease that may have altered refraction. All subjects were willing to wear bifocal spectacle lenses for 30 months.
B: Inclusion Criteria:

Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year.

-

Exclusion Criteria:

Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma)

-
C: Inclusion Criteria:

* All the students in Grade 1

Exclusion Criteria:

* No
D: Inclusion Criteria:

* Age: 8 to 13 years
* Myopia: -1.00 to -5.00 D
* Myopia progression: at least 0.50 D/yr
* Astigmatism and anisometropia: not more than 1.50 D
* Distance monocular visual acuity: 6/6 or better
* Near monocular visual acuity: 0.4 M or better
* Stereoacuity: not more than 40 sec of arc at 40 cm

Exclusion Criteria:

* Strabismus
* Ocular diseases

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.


Options:
A: INCLUSION CRITERIA

1. DISEASE CHARACTERISTICS:

   * Healthy male physicians practicing in the United States
   * Prior participation in the Physicians' Health Study I allowed
2. PATIENT CHARACTERISTICS:

   * Aged 50 years and over
   * No history of serious illness that would preclude study participation
   * No history of significant adverse events (e.g., rash or allergic reaction) attributed to study agents
3. PRIOR CONCURRENT THERAPY:

   * No other concurrent vitamin and/or multivitamin supplementation
   * No concurrent vitamin K-depleting anticoagulants (e.g., warfarin)
B: Inclusion Criteria:

* Healthy women
* No previous history of cardiovascular disease or cancer
* No contraindications to aspirin or vitamin E
C: Women, aged 40 and over, at high risk, with a history of cardiovascular disease or three or more coronary heart disease risk factors.
D: Inclusion Criteria:

* Men aged between 18 and 35 years, nonsmokers
* Body mass index between 15th and 85th percentile
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
* Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
* Normal ophthalmic findings, ametropia \< 3 Dpt

Exclusion Criteria:

* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
* Treatment in the previous 3 weeks with any drug, vitamins and minerals supplements as well
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
* History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with, distribution, metabolism or excretion of study drugs
* Blood donation during the previous 3 weeks

Answer: B